Filgotinib for treating moderately to severely active ulcerative colitis

2.1 Filgotinib (Jyseleca, Galapagos) is indicated for treating moderately to severely active ulcerative colitis in adults when conventional or biological treatment cannot be tolerated, or the disease has responded inadequately or lost response to treatment.

2.2 The dosage schedule is available in the summary of product characteristics for filgotinib.

2.3 The price for filgotinib is £863.10 per bottle for thirty 200‑mg tablets (BNF online, accessed March 2022). The average cost for each patient per year is estimated at £10,508 based on the list price.

2.4 The company has a commercial arrangement. This makes filgotinib available to the NHS with a discount. The size of the discount is commercial in confidence. It is the company's responsibility to let relevant NHS organisations know details of the discount.